


Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, of

formula (1)



[wherein

R¹ and R² are independently of each other C₁₋₆ alkyl group {the C₁₋₆ alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom), C₂₋₆ alkenyl group or C₂₋₆ alkynyl group (the C₂₋₆ alkenyl group and C₂₋₆ alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom))), or -L¹-NR³R⁴ {R³ and R⁴ are independently of each other C₁₋₆ alkyl group (the C₁₋₆ alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom)) or phenyl group (wherein the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom), L¹ is C₂₋₆ alkylene group (the C₂₋₆ alkylene group may be substituted with C₁₋₃ alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom, C₁₋₃ alkyl group or C₁₋₃ alkoxy group))}, or

R¹ and R² together form -CR⁵R⁶-CR⁷R⁸-, -CR⁵R⁶-CR⁷R⁸-CR⁹R¹⁰- or -CR⁵R⁶-CR⁷R⁸-CR⁹R¹⁰-CR¹¹R¹²- (R⁵ to R¹² are independently of each other hydrogen atom or C₁₋₆ alkyl

group, or any two of them together with the carbon atom bonding them may form 5-, 6- or 7-membered ring);


X^1 and X^2 are independently of each other O or NR¹³ (R¹³ is hydrogen atom or C₁₋₆ alkyl group);

Ar is phenyl group, pyridyl group, furyl group or 2,1,3-benzoxadiazol-4-yl group {the phenyl group, pyridyl group, furyl group and 2,1,3-benzoxadiazol-4-yl group may arbitrarily substituted with one or two substituents selected from NO₂, CF₃, Br, Cl, F, R (R is C₁₋₂₀ alkyl group), OH, OR¹⁴ (R¹⁴ is C₁₋₆ alkyl group), OCHF₂, COOR¹⁴, NH₂, NHR¹⁴, NR¹⁴R¹⁵ (R¹⁵ is C₁₋₆ alkyl group), CONH₂, CONHR¹⁴, CONR¹⁴R¹⁵, COSR¹⁴, SR¹⁴, S(O)R¹⁴, S(O)₂R¹⁴, SO₃H, SO₃R¹⁴, SO₂NH₂, SO₂NHR¹⁴, SO₂NR¹⁴R¹⁵, CN and phenoxy group};

R^a and R^b are independently of each other C₁₋₆ alkyl group, -L²-NR¹⁶R¹⁷ {R¹⁶ and R¹⁷ are independently of each other hydrogen atom, C₁₋₆ alkyl group (the C₁₋₆ alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom) or phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom), L² is C₂₋₆ alkylene group (the C₂₋₆ alkylene group may be arbitrarily substituted with C₁₋₃ alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom, C₁₋₃ alkyl group or C₁₋₃ alkoxy group))), CH₂O-L²-NR¹⁶R¹⁷, Ar¹ (Ar¹ is phenyl group (the phenyl group may be arbitrarily substituted with halogen atom, C₁₋₃ alkyl group or C₁₋₃ alkoxy group)), CH=CHAR¹, CH₂CH(OH)Ar¹, CHO, CN, CH₂OH, CHOR¹⁶, -L²-N(CH₂CH₂)₂NR¹⁶ or NR¹⁶R¹⁷;

Y is C₁₋₂₀ alkyl group {the C₁₋₂₀ alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom), C₂₋₆ alkenyl group or C₂₋₆ alkynyl group (the C₂₋₆ alkenyl group and C₂₋₆ alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom))), -L³-NR¹⁸R¹⁹ {R¹⁸ and R¹⁹ are independently of each other


C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C_{1-6} alkoxy group or halogen atom) or phenyl group (the phenyl group may be substituted with C_{1-6} alkoxy group or halogen atom), L^3 is C_{2-6} alkylene group (the C_{2-6} alkylene group may be arbitrarily substituted with C_{1-3} alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom, C_{1-3} alkyl group or C_{1-3} alkoxy group))},



(wherein o and p are independently of each other 3 or 4, q is 1, 2 or 3), and

* is absolute configuration of R.]

2. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 1, wherein Y is $-L^3-NR^{18}R^{19}$ { R^{18} and R^{19} are independently of each other C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C_{1-6} alkoxy group or halogen atom) or phenyl group (the phenyl group may be substituted with C_{1-6} alkoxy group or halogen atom), L^3 is C_{2-6} alkylene group (the C_{2-6} alkylene group may be arbitrarily substituted with C_{1-3} alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom, C_{1-3} alkyl group or C_{1-3} alkoxy group))},



(wherein o and p are independently of each other 3 or 4, q is 1, 2 or 3), and

R^a is C₁₋₆ alkyl group.

3. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 2, wherein R^b is C₁₋₆ alkyl group, CN or NH₂.

4. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 1, wherein Y is C₁₋₂₀ alkyl group {the C₁₋₂₀ alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom), C₂₋₆ alkenyl group or C₂₋₆ alkynyl group (the C₂₋₆ alkenyl group and C₂₋₆ alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom))},

R^b is -L²-NR¹⁶R¹⁷ {R¹⁶ and R¹⁷ are independently of each other hydrogen atom, C₁₋₆ alkyl group (the C₁₋₆ alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom)) or phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom)}, L² is C₂₋₆ alkylene group (the C₂₋₆ alkylene group may be arbitrarily substituted with C₁₋₃ alkyl group or phenyl group (the

phenyl group may be arbitrarily substituted with halogen atom, C₁₋₃ alkyl group or C₁₋₃ alkoxy group)), CH₂O-L²-NR¹⁶R¹⁷ or -L²-N(CH₂CH₂)₂NR¹⁶, and

R^a is C₁₋₆ alkyl group.

5. (Currently Amended) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 2, 3 or 4, wherein R¹ and R² are independently of each other C₁₋₆ alkyl group {the C₁₋₆ alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom), C₂₋₆ alkenyl group or C₂₋₆ alkynyl group (the C₂₋₆ alkenyl group and C₂₋₆ alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with C₁₋₆ alkoxy group or halogen atom))), or R¹ and R² together form -CR⁵R⁶-CR⁷R⁸-, -CR⁵R⁶-CR⁷R⁸-CR⁹R¹⁰- or -CR⁵R⁶-CR⁷R⁸-CR⁹R¹⁰-CR¹¹R¹²- (R⁵ to R¹² are independently of each other hydrogen atom or C₁₋₆ alkyl group, or any two of them together with the carbon atom bonding them may form 5-, 6- or 7-membered ring); X¹ and X² are both O.

6. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 5, wherein Ar is phenyl, 3-nitrophenyl, 2-nitrophenyl, 3-chlorophenyl, 2-chlorophenyl, 3-methoxyphenyl, 2-methoxyphenyl, 2-trifluoromethylphenyl, 2-trifluoromethylphenyl or 2,3-dichlorophenyl.

7. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 6, wherein R¹ and R² together form -CH₂-C(CH₃)₂-CH₂-, X¹ and X² are

both O, Ar is 3-nitrophenyl, R^a and R^b are both methyl, and Y is 2-[benzyl(phenyl)amino]ethyl.

8. (Currently Amended) A pharmaceutical containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

9. (Currently Amended) A therapeutic or preventive agent against a disease for which T-type calcium channel blocking action is effective, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

10. (Currently Amended) A therapeutic or preventive agent against hypercardia, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

11. (Currently Amended) A therapeutic or preventive agent against heart failure, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

12. (Currently Amended) A therapeutic or preventive agent against cardiomyopathy, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

13. (Currently Amended) A therapeutic or preventive agent against atrial fibrillation, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

14. (Currently Amended) A therapeutic or preventive agent against tachycardia-arrhythmia, containing the T-type calcium channel blocker according to ~~any one of claims 1~~

~~to 7 claim 1.~~

15. (Currently Amended) A therapeutic or preventive agent against arterial sclerosis, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

16. (Currently Amended) A therapeutic or preventive agent against nephritis, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

17. (Currently Amended) A therapeutic or preventive agent against nephropathy, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

18. (Currently Amended) A therapeutic or preventive agent against renal disorder, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

19. (Currently Amended) A therapeutic or preventive agent against renal insufficiency, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

20. (Currently Amended) A therapeutic or preventive agent against edema, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

21. (Currently Amended) A therapeutic or preventive agent against inflammation, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

22. (Currently Amended) A therapeutic or preventive agent against hyper-
aldosteronism, containing the T-type calcium channel blocker according to ~~any one of claims
1 to 7~~claim 1.

23. (Currently Amended) A therapeutic or preventive agent against neurogenic pain,
containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

24. (Currently Amended) A therapeutic or preventive agent against epilepsy,
containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.